Test helps target glioblastoma patients most likely to benefit from bevacizumab
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin), according to new research from The University of Texas MD Anderson Cancer Center.
Jun 2, 2013
0
0